
Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease
Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease Vancouver, BC, May 12, 2025--(T-Net)--Algernon Pharmaceuticals Inc. (CSE: AGN), a Canadian clinical stage pharmaceutical development company …